Cancer Progress and Priorities : Gastric Cancer
©2023 American Association for Cancer Research..
Gastric cancer, the fifth leading cause of cancer worldwide, is estimated to be responsible for approximately 1.4% of all new cancers and 1.8% of all cancer-related deaths in the United States. Despite declining incidence rates and improved survival rates, however, gastric cancer continues to disproportionately affect racial and ethnic minorities and individuals of lower socioeconomic status at higher rates than the general population. To improve outcomes globally and address disparities within the United States, continued improvements are needed in risk factor modification and biomarker development and to improve access to existing preventative measures such as genetic testing and H. pylori eradication testing, in addition to expanding upon current clinical guidelines for premalignant disease to address gaps in endoscopic surveillance and early detection.
| Errataetall: |
CommentIn: Cancer Epidemiol Biomarkers Prev. 2023 Sep 1;32(9):1271. - PMID 37655425 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 32(2023), 4 vom: 03. Apr., Seite 473-486 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alagesan, Priya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 04.04.2023 Date Revised 04.10.2023 published: Print CommentIn: Cancer Epidemiol Biomarkers Prev. 2023 Sep 1;32(9):1271. - PMID 37655425 Citation Status MEDLINE |
|---|
| doi: |
10.1158/1055-9965.EPI-22-0994 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355145235 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355145235 | ||
| 003 | DE-627 | ||
| 005 | 20231226063728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1055-9965.EPI-22-0994 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM355145235 | ||
| 035 | |a (NLM)37009691 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alagesan, Priya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer Progress and Priorities |b Gastric Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2023 | ||
| 500 | |a Date Revised 04.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Cancer Epidemiol Biomarkers Prev. 2023 Sep 1;32(9):1271. - PMID 37655425 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 American Association for Cancer Research. | ||
| 520 | |a Gastric cancer, the fifth leading cause of cancer worldwide, is estimated to be responsible for approximately 1.4% of all new cancers and 1.8% of all cancer-related deaths in the United States. Despite declining incidence rates and improved survival rates, however, gastric cancer continues to disproportionately affect racial and ethnic minorities and individuals of lower socioeconomic status at higher rates than the general population. To improve outcomes globally and address disparities within the United States, continued improvements are needed in risk factor modification and biomarker development and to improve access to existing preventative measures such as genetic testing and H. pylori eradication testing, in addition to expanding upon current clinical guidelines for premalignant disease to address gaps in endoscopic surveillance and early detection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 700 | 1 | |a Goodwin, Jessica C |e verfasserin |4 aut | |
| 700 | 1 | |a Garman, Katherine S |e verfasserin |4 aut | |
| 700 | 1 | |a Epplein, Meira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology |d 1992 |g 32(2023), 4 vom: 03. Apr., Seite 473-486 |w (DE-627)NLM012651702 |x 1538-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:4 |g day:03 |g month:04 |g pages:473-486 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1055-9965.EPI-22-0994 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 4 |b 03 |c 04 |h 473-486 | ||